UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Podcast on the Challenges and Recommendations to Address Unmet Needs in MS for LGBTQ+ Populations in the United States

Neurology and therapy, 2023-10, Vol.12 (5), p.1399-1407

2023

Volltextzugriff (PDF)

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1

BMC neurology, 2018-09, Vol.18 (1), p.143-143, Article 143

2018

Volltextzugriff (PDF)

Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

BMC neurology, 2018-05, Vol.18 (1), p.68-68, Article 68

2018

Volltextzugriff (PDF)

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

BMC neurology, 2012-12, Vol.12 (1), p.154-154, Article 154

2012

Volltextzugriff (PDF)

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

The Lancet (British edition), 2012-11, Vol.380 (9856), p.1829-1839

2012

Volltextzugriff (PDF)

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

Annals of neurology, 2009-10, Vol.66 (4), p.460-471

2009

Volltextzugriff (PDF)

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Lancet neurology, 2021-12, Vol.20 (12), p.1001-1011

2021

Volltextzugriff (PDF)

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity

Multiple sclerosis, 2021-05, Vol.27 (6), p.883-894

2021

Volltextzugriff (PDF)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Neurology, 2016-11, Vol.87 (19), p.1985

2016

Volltextzugriff (PDF)

Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS

Multiple sclerosis and related disorders, 2020-08, Vol.43, p.102158-102158, Article 102158

2020

Volltextzugriff (PDF)

Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study

Multiple sclerosis and related disorders, 2018-10, Vol.25, p.50-56

2018

Volltextzugriff (PDF)

Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial

Therapeutic advances in neurological disorders, 2018-01, Vol.11, p.1756286418774338-1756286418774338

2018

Volltextzugriff (PDF)

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study

Neurology : neuroimmunology & neuroinflammation, 2018-09, Vol.5 (5), p.e477-e477

2018

Volltextzugriff (PDF)

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

Neurology, 2009-11, Vol.73 (18), p.1493

2009

Volltextzugriff (PDF)

Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study

Expert opinion on drug delivery, 2011-12, Vol.8 (12), p.1543-1553

2011

Volltextzugriff (PDF)

Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes

Multiple sclerosis and related disorders, 2020-10, Vol.45, p.102346-102346, Article 102346

2020

Volltextzugriff (PDF)

Phase IV study of retention on fingolimod injectable multiple sclerosis therapies: a randomized clinical trial

Therapeutic advances in neurological disorders, 2018-05, Vol.11

2018

Volltextzugriff (PDF)

Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design

Journal of medical economics, 2013-07, Vol.16 (7), p.859-865

2013

Volltextzugriff (PDF)

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferon[beta]-1a versus subcutaneous interferon[beta]-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

BMC neurology, 2012-12, Vol.12 (1), p.154-154

2012

Volltextzugriff (PDF)

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

Multiple sclerosis and related disorders, 2014-09, Vol.3 (5), p.620-628

2014

Volltextzugriff (PDF)

A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis

Multiple sclerosis, 2005-10, Vol.11 (5), p.585-591

2005

Volltextzugriff (PDF)

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma

Gastroenterology (New York, N.Y. 1943), 2018-03, Vol.154 (4), p.1066-1079.e5

2018

Volltextzugriff (PDF)

Abstract 1069: MiR-21 may serve as a predictive biomarker of response in the assessment of efficacy of HSP-90 inhibition in gastrointestinal (GI) cancers

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1069-1069

2016

Volltextzugriff (PDF)

To the editor

National review (New York), 1964-12, Vol.16 (50), p.1086

1964

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(23)
magazinearticle
(1)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(15)
Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Multiple Sclerosis
(13)
Clinical Neurology
(12)
Female
(12)
Male
(12)
Neurosciences & Neurology
(12)
Middle Aged
(11)
Adult
(10)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(10)
Treatment Outcome
(9)
Neurology
(7)
Adolescent
(6)
Interferon Beta-1a
(5)
Neurosciences
(5)
Adjuvants, Immunologic - Administration & Dosage
(4)
Aged
(4)
Clinical Trials
(4)
Disease Progression
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Podcast on the Challenges and Recommendations to Address Unmet Needs in MS for LGBTQ+ Populations in the United States

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1

Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS

Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study

Phase IV study of retention on fingolimod versus injectable multiple sclerosis therapies: a randomized clinical trial

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study

Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes

Phase IV study of retention on fingolimod injectable multiple sclerosis therapies: a randomized clinical trial

Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferon[beta]-1a versus subcutaneous interferon[beta]-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis

A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma

Abstract 1069: MiR-21 may serve as a predictive biomarker of response in the assessment of efficacy of HSP-90 inhibition in gastrointestinal (GI) cancers

To the editor

Suchergebnisse filtern